These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 24135335

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia.
    Kipfer S, Stephan MA, Schüpbach WM, Ballinari P, Kaelin-Lang A.
    Arch Neurol; 2011 Aug; 68(8):1037-9. PubMed ID: 21825240
    [Abstract] [Full Text] [Related]

  • 3. Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.
    Suh DC, Pahwa R, Mallya U.
    J Neurol Sci; 2012 Aug 15; 319(1-2):24-31. PubMed ID: 22664154
    [Abstract] [Full Text] [Related]

  • 4. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE.
    Mov Disord; 2005 Mar 15; 20(3):342-4. PubMed ID: 15580606
    [Abstract] [Full Text] [Related]

  • 5. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
    Thanvi B, Lo N, Robinson T.
    Postgrad Med J; 2007 Jun 15; 83(980):384-8. PubMed ID: 17551069
    [Abstract] [Full Text] [Related]

  • 6. Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade).
    Sharma JC, Macnamara L, Hasoon M, Vassallo M, Ross I.
    Parkinsonism Relat Disord; 2006 Dec 15; 12(8):499-505. PubMed ID: 16935018
    [Abstract] [Full Text] [Related]

  • 7. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F, Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators.
    Mov Disord; 2013 Jul 15; 28(8):1064-71. PubMed ID: 23630119
    [Abstract] [Full Text] [Related]

  • 8. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S, Pradhan R, Paul P, Das M, Gupta A, Ghosh P, Chatterjee S.
    Neurol Res; 2014 Sep 15; 36(9):841-6. PubMed ID: 24601722
    [Abstract] [Full Text] [Related]

  • 9. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ, Molina JA, Ortí-Pareja M.
    Rev Neurol; 2014 Sep 15; 28(9):889-98. PubMed ID: 10390756
    [Abstract] [Full Text] [Related]

  • 10. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
    Nicoletti A, Mostile G, Nicoletti G, Arabia G, Iliceto G, Lamberti P, Marconi R, Morgante L, Barone P, Quattrone A, Zappia M.
    J Neurol; 2016 May 15; 263(5):888-894. PubMed ID: 26964541
    [Abstract] [Full Text] [Related]

  • 11. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF, Gao J, Durairajan SS, Man SC, Xie LX, Lu JH, Fong WL, Li M.
    J Clin Neurosci; 2009 Aug 15; 16(8):1034-7. PubMed ID: 19428256
    [Abstract] [Full Text] [Related]

  • 12. Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.
    Hashim HZ, Norlinah MI, Nafisah WY, Tan HJ, Raymond AA, Tamil AM.
    Int J Neurosci; 2014 Mar 15; 124(3):187-91. PubMed ID: 23952588
    [Abstract] [Full Text] [Related]

  • 13. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
    Stathis P, Konitsiotis S, Tagaris G, Peterson D, VALID-PD Study Group.
    Mov Disord; 2011 Feb 01; 26(2):264-70. PubMed ID: 21412833
    [Abstract] [Full Text] [Related]

  • 14. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
    Morgante F, Espay AJ, Gunraj C, Lang AE, Chen R.
    Brain; 2006 Apr 01; 129(Pt 4):1059-69. PubMed ID: 16476674
    [Abstract] [Full Text] [Related]

  • 15. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
    Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL, 228 Study Investigators.
    Mov Disord; 2010 May 15; 25(7):858-66. PubMed ID: 20461803
    [Abstract] [Full Text] [Related]

  • 16. Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.
    Cerasa A, Salsone M, Morelli M, Pugliese P, Arabia G, Gioia CM, Novellino F, Quattrone A.
    Parkinsonism Relat Disord; 2013 Oct 15; 19(10):883-8. PubMed ID: 23769805
    [Abstract] [Full Text] [Related]

  • 17. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease.
    Lee JY, Cho J, Lee EK, Park SS, Jeon BS.
    Mov Disord; 2011 Jan 15; 26(1):73-9. PubMed ID: 20945430
    [Abstract] [Full Text] [Related]

  • 18. The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia.
    Molchadski I, Korczyn AD, Cohen OS, Katzav A, Nitzan Z, Chapman J, Hassin-Baer S.
    Acta Neurol Scand; 2011 Feb 15; 123(2):117-21. PubMed ID: 21108621
    [Abstract] [Full Text] [Related]

  • 19. [Incidence and determinants of levodopa-induced dyskinesia in a retrospective cohort of Mexican patients with Parkinson's disease].
    Cervantes-Arriaga A, Rodríguez-Violante M, Salmerón-Mercado M, Calleja-Castillo J, Corona T, Yescas P, Alonso-Vilatela E.
    Rev Invest Clin; 2012 Feb 15; 64(3):220-6. PubMed ID: 23045943
    [Abstract] [Full Text] [Related]

  • 20. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.
    Strong JA, Dalvi A, Revilla FJ, Sahay A, Samaha FJ, Welge JA, Gong J, Gartner M, Yue X, Yu L.
    Mov Disord; 2006 May 15; 21(5):654-9. PubMed ID: 16435402
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.